Avatrombopag (maleate) (Standard)

Avatrombopag (maleate) (Standard) is the analytical standard of Avatrombopag (maleate) . This product is intended for research and analytical applications. Avatrombopag maleate (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM) . Avatrombopag maleate mimics the biological activities of TPO. Avatrombopag maleate increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag maleate is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].

Product Specifications

CAS Number

[677007-74-8]

UNSPSC

12352100

Target

Cytochrome P450; ERK; Reference Standards; STAT; Thrombopoietin Receptor

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Others; Stem Cell/Wnt

Field of Research

Inflammation/Immunology; Cancer

Smiles

O=C(C1CCN(C2=NC=C(C(NC3=NC(C4=CC(Cl)=CS4)=C(N5CCN(C6CCCCC6)CC5)S3)=O)C=C2Cl)CC1)O.O=C(O)/C=C\C(O)=O

Molecular Formula

C33H38Cl2N6O7S2

Molecular Weight

765.73

References & Citations

[1]Fukushima-Shintani M, et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009;82 (4) :247-254.|[2]Xu H, et al. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Expert Rev Clin Pharmacol. 2019;12 (9) :859-865.|[3]Nomoto M, Zamora CA, Schuck E, et al. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Br J Clin Pharmacol. 2018;84 (5) :952-960.